Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Steve Ammons"'
Autor:
Charles P. Hart, Mark D. Matteucci, John G. Curd, W. Steve Ammons, Jian-Xin Duan, Yan Wang, Damien Ferraro, Dharmendra Ahluwalia, Jingli Wang, Qian Liu, Jessica D. Sun
PDF file - 2.7MB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6fcaedba61d40db0e601de0a736eb65
https://doi.org/10.1158/1078-0432.22443263
https://doi.org/10.1158/1078-0432.22443263
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 9, Iss 8, Pp 625-633 (2007)
Glufosfamide is an alkylating agent consisting of iphosphoramide mustard conjugated to glucose that is currently included in clinical studies of pancreatic cancer. We studied the effects of glufosfamide, in combination with gemcitabine, on in vitro,
Externí odkaz:
https://doaj.org/article/79a178d1594a4dfb8bbe9eca69de9786
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 5, Iss 6, Pp 489-494 (2003)
ING-1(heMAb), a human-engineered monoclonal antibody (MAb) that specifically targets the epithelial cell adhesion molecule (Ep-CAM), kills adenocarcinoma cells in vitro and inhibits tumor growth in vivo. In the current study, we evaluated the efficac
Externí odkaz:
https://doaj.org/article/7005ae2224884dcf9ef771dac345907a
Autor:
W. Steve Ammons, Robert J. Bauer, Arnold H. Horwitz, Zhi J. Chen, Eddie Bautista, Harry H. Ruan, Marina Abramova, Kristen R. Scott, Russell L. Dedrick
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 5, Iss 2, Pp 146-154 (2003)
ING-1(heMAb), a Human Engineered™ monoclonal antibody to epithelial cell adhesion molecule (Ep-CAM ), was evaluated for its in vitro and in vivo activity. The dissociation constant of ING-1(heMAb) for binding to Ep-CAM on HT-29 human colon tumor ce
Externí odkaz:
https://doaj.org/article/b4ec14f2d88f4787824412af41c6a203
Autor:
Yan Wang, Damien Ferraro, Dharmendra Ahluwalia, W. Steve Ammons, Mark D. Matteucci, Lee D. Cranmer, Jian Xin Duan, Jessica D Sun, John G. Curd, Charles P. Hart, Qian Liu, Amanda F. Baker, Jingli Wang
Publikováno v:
Cancer Chemotherapy and Pharmacology. 69:1487-1498
Subregional hypoxia is a common feature of tumors and is recognized as a limiting factor for the success of radiotherapy and chemotherapy. TH-302, a hypoxia-activated prodrug selectively targeting hypoxic regions of solid tumors, delivers a cytotoxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fd42d9f797424a8f6e4333a6d6351a1
https://doi.org/10.1007/s00280-012-1852-8
https://doi.org/10.1007/s00280-012-1852-8
Autor:
W. Steve Ammons, Damien Ferraro, Jingli Wang, Qian Liu, Yan Wang, Charles P. Hart, Dharmendra Ahluwalia, Jian-Xin Duan, John G. Curd, Mark D. Matteucci, Jessica D Sun
Publikováno v:
Clinical Cancer Research. 18:758-770
Purpose: Tumor hypoxia underlies treatment failure and yields a more aggressive, invasive, and metastatic cancer phenotype. TH-302 is a 2-nitroimidazole triggered hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM). The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c65d1b1f4b21b090fd54e26f2f950006
https://doi.org/10.1158/1078-0432.ccr-11-1980
https://doi.org/10.1158/1078-0432.ccr-11-1980
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 9, Iss 8, Pp 625-633 (2007)
Glufosfamide is an alkylating agent consisting of iphosphoramide mustard conjugated to glucose that is currently included in clinical studies of pancreatic cancer. We studied the effects of glufosfamide, in combination with gemcitabine, on in vitro a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b461a75dfbf8c698765c873496f45638
https://doi.org/10.1593/neo.07343
https://doi.org/10.1593/neo.07343
Autor:
Rossana Nadell, Arnold Horwitz, Russell L. Dedrick, Robert E. Williams, W. Steve Ammons, Robert J. Bauer, Pei-Syan Liu
Publikováno v:
Journal of Endotoxin Research. 10:97-106
rBPI23, a recombinant N-terminal fragment of human bactericidal/permeability-increasing protein (BPI), kills Gram-negative bacteria and neutralizes endotoxin. rBPI21, a variant in which cysteine 132 is changed to alanine, retains the activities of rB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0fe53ae31aebeb5542a2774cd10279a5
https://doi.org/10.1177/09680519040100020501
https://doi.org/10.1177/09680519040100020501
Autor:
Arnold H. Horwitz, W. Steve Ammons, Robert J. Bauer, Russell Dedrick, Rossana Nadell, Robert E. Williams, Pei-Syan Liu
Publikováno v:
Journal of Endotoxin Research. 10:97-106
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3d46a03495209f9b179e9c1b92372aa
https://doi.org/10.1179/096805104225003843
https://doi.org/10.1179/096805104225003843
Publikováno v:
Journal of Veterinary Internal Medicine. 15:355-360
We evaluated the ability of an antimicrobial and endotoxin-neutralizing agent, the recombinant amino terminal fragment of bactericidal permeability-increasing protein (rBPI21), to decrease plasma endotoxin concentration and severity of clinical signs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09fc55724598a5f306513ad3ff903715
https://doi.org/10.1111/j.1939-1676.2001.tb02329.x
https://doi.org/10.1111/j.1939-1676.2001.tb02329.x